4205-90-7 Usage
Uses
Different sources of media describe the Uses of 4205-90-7 differently. You can refer to the following data:
1. Antihypertensive.
2. Clonidine
may be useful in the treatment of acute opioid withdrawal. Epidural
clonidine 1–2μgkg –1 increases the duration and potency of analgesia
provided by epidural opioid or local anaesthetic drugs.
Definition
ChEBI: A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Brand name
Catapres (Boehringer
Ingelheim).
Pharmacokinetics
Clonidine is lipid soluble and rapidly absorbed after oral administration,
with a peak plasma concentration occurring in 60–90min. O ral, intravenous
and intramuscular routes may be used for sedation or analgesia. I n addition,
epidural and intrathecal clonidine is used to augment regional anaesthesia,
but perineural administration is of limited or no effect. The elimination halflife
is 9–13h and is prolonged in renal failure. Fifty percent of an
administered dose is excreted unchanged by the kidneys, and 50% is
metabolised in the liver to inactive metabolites.
Physiological effects
Different sources of media describe the Physiological effects of 4205-90-7 differently. You can refer to the following data:
1. CNS effects
Clonidine produces sedation, anxiolysis and analgesia. I t also has a MA Csparing
effect, but there is a ceiling to the reduction because of the potential
for activity at α1 receptors when used at higher doses.
CVS effects
The cardiovascular effects of clonidine probably involve α1 receptors and
imidazoline receptors as with dexmedetomidine. Clonidine lowers the set
point around which arterial pressure is regulated.
Respiratory effects
Clonidine has minor respiratory effects, causing only a small reduction in
minute ventilation.
2. Clonidine has some effects at α1-receptors (α2/ α1 > 200 : 1).
Clonidine reduces the MA C of inhalational anaesthetic agents by up to 50%.
I t has a synergistic analgesic effect with opioids which may be partly
pharmacokinetic because the elimination half-life of opioids is also
increased.
Metabolic pathway
Clonidine is well absorbed orally, with peak plasma
concentrations after 60–90min. I t is highly lipid soluble, and approximately
50% is metabolised in the liver to inactive metabolites; the rest is excreted
unchanged via the kidneys, with an elimination half-life of 9–12h.
Check Digit Verification of cas no
The CAS Registry Mumber 4205-90-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,2,0 and 5 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 4205-90:
(6*4)+(5*2)+(4*0)+(3*5)+(2*9)+(1*0)=67
67 % 10 = 7
So 4205-90-7 is a valid CAS Registry Number.
InChI:InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)
4205-90-7Relevant articles and documents
-
Staehle et al.
, p. 839,842 (1978)
-
Heterocyclic compounds as FGFR4 inhibitors
-
Paragraph 0257-0262, (2021/02/10)
The present invention provides heterocyclic compounds as selective inhibitors of fibroblast growth factor receptor 4 (FGFR4), pharmaceutical compositions containing the compounds, methods of preparingthe compounds, and methods of treating cell proliferative diseases, such as cancer, using the compounds of the invention.
Efficient synthesis of 2-arylamino-2-imidazolines and 2-aminobenzimidazoles with aminoiminomethanesulfonic acid derivatives
Mohanazadeh, Farajollah,Nami, Navabe,Hosseini, Samine Sadat
experimental part, p. 1055 - 1058 (2012/01/04)
A highly efficient synthesis of 2-arylamino-2-imidazolines and 2-aminobenzimidazoles from aminoiminomethanesulfonic acid derivatives is described. The method is simple and practical, generating imidazoline and benzimidazoline derivatives in excellent isolated yields.
